Osteosarcoma – Overview of Information and Clinical Research

Cancer research · Osteosarcoma

For young adults, the standard chemotherapy drug combination used for osteosarcoma includes high‑dose methotrexate, doxorubicin, and cisplatin (MAP).

Osteosarcoma is a primary bone cancer that primarily affects adolescents and young adults. It commonly arises in the long bones near joints and is treated with surgery plus systemic chemotherapy, usually a high‑dose methotrexate, doxorubicin, and cisplatin (MAP) regimen. The 5‑year survival for localized disease is 60‑70%, whereas metastatic disease has a much poorer prognosis.

This standard MAP regimen has been the cornerstone of osteosarcoma therapy for over four decades and remains the benchmark against which new systemic therapies are evaluated.

Evidence level: Állatkísérletes. Állatmodellben vizsgálták.

Original source

Related signals